Today StocksHaven Investments has some exciting news to share with you all. Due to the influx of emails we have been receiving lately on inquiries regarding the latest FDA deadlines on (Public, AMEX:HEB) and (Public, OTC:ACUS), StocksHaven Investments has requested a phone conference with Hemispherx BioPharma, Inc. as per their investor relations spokesperson. Rest assured [...]



